BriaCell Therapeutics Corp. (TSE:BCT – Get Free Report)’s share price rose 0.9% during mid-day trading on Thursday . The stock traded as high as C$5.77 and last traded at C$5.73. Approximately 23,384 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 43,565 shares. The stock had previously closed at C$5.68.
BriaCell Therapeutics Stock Performance
The firm has a market cap of C$35.59 million, a price-to-earnings ratio of -0.17 and a beta of 2.15. The company’s fifty day moving average is C$10.37 and its two-hundred day moving average is C$12.16.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.
Read More
- Five stocks we like better than BriaCell Therapeutics
- Your Bank Account Is No Longer Safe
- When to buy gold (mathematically)
- What a Former CIA Agent Knows About the Coming Collapse
- Nervous about the stock market? Read this
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
